Richard E. Lowenthal

Insider Reports History

Entity
Individual
Location
12481 High Bluff Drive, Suite 200, San Diego, CA
Signature
/s/ Kathleen Scott, Attorney-in-Fact
All insider transactions
Transactions in reports broken out by “transaction date” reported in original SEC filing, see here for transactions aggregated across transaction date

Holdings reported by Richard E. Lowenthal:

Stock Role Class Num Shares Value Price $ Report Date Ownership
ARS Pharmaceuticals, Inc. PRESIDENT AND CEO, Director, 10%+ Owner Common Stock 4.32M $76.1M $17.64 Nov 12, 2024 Direct
ARS Pharmaceuticals, Inc. PRESIDENT AND CEO, Director, 10%+ Owner Common Stock 3.41M $60.1M $17.64 Nov 12, 2024 By Spouse
ARS Pharmaceuticals, Inc. PRESIDENT AND CEO, Director, 10%+ Owner Common Stock 1.4M $24.7M $17.64 Nov 12, 2024 By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020
ARS Pharmaceuticals, Inc. PRESIDENT AND CEO, Director, 10%+ Owner Common Stock 1.3M $22.9M $17.64 Nov 12, 2024 By Richard E. Lowenthal Charitable Remainder UniTrust Dated January 7, 2020
ARS Pharmaceuticals, Inc. PRESIDENT AND CEO, Director, 10%+ Owner Common Stock 1.25M $22M $17.64 Nov 12, 2024 By Lowenthal-Tanimoto Family Trust U/A DTD 4/3/2006
ARS Pharmaceuticals, Inc. PRESIDENT AND CEO, Director, 10%+ Owner Stock Option (right to buy) 34.5K Apr 23, 2024 By Spouse

Insider Reports Filed by Richard E. Lowenthal

Symbol Company Period Transactions Value $ Form Type Date Filed Role
SPRY ARS Pharmaceuticals, Inc. Nov 12, 2024 4 -$1.68M 4 Nov 14, 2024 PRESIDENT AND CEO, Director, 10%+ Owner
SPRY ARS Pharmaceuticals, Inc. Oct 15, 2024 3 -$1.49M 4 Oct 17, 2024 PRESIDENT AND CEO, Director, 10%+ Owner
SPRY ARS Pharmaceuticals, Inc. Oct 8, 2024 2 -$1.38M 4 Oct 10, 2024 PRESIDENT AND CEO, Director, 10%+ Owner
SPRY ARS Pharmaceuticals, Inc. Sep 17, 2024 2 -$1.29M 4 Sep 19, 2024 PRESIDENT AND CEO, Director, 10%+ Owner
SPRY ARS Pharmaceuticals, Inc. Sep 10, 2024 2 -$1.15M 4 Sep 12, 2024 PRESIDENT AND CEO, Director, 10%+ Owner
SPRY ARS Pharmaceuticals, Inc. Aug 20, 2024 6 -$1.5M 4 Aug 21, 2024 PRESIDENT AND CEO, Director, 10%+ Owner
SPRY ARS Pharmaceuticals, Inc. Aug 13, 2024 4 -$1.25M 4 Aug 15, 2024 PRESIDENT AND CEO, Director, 10%+ Owner
SPRY ARS Pharmaceuticals, Inc. Jul 16, 2024 2 -$1.14M 4 Jul 18, 2024 PRESIDENT AND CEO, Director, 10%+ Owner
SPRY ARS Pharmaceuticals, Inc. Jul 9, 2024 2 -$962K 4 Jul 11, 2024 PRESIDENT AND CEO, Director, 10%+ Owner
SPRY ARS Pharmaceuticals, Inc. Jun 11, 2024 4 -$914K 4 Jun 13, 2024 PRESIDENT AND CEO, Director, 10%+ Owner
SPRY ARS Pharmaceuticals, Inc. May 14, 2024 6 -$905K 4 May 16, 2024 PRESIDENT AND CEO, Director, 10%+ Owner
SPRY ARS Pharmaceuticals, Inc. May 7, 2024 2 -$934K 4 May 9, 2024 PRESIDENT AND CEO, Director, 10%+ Owner
SPRY ARS Pharmaceuticals, Inc. Apr 23, 2024 4 $139K 4 Apr 24, 2024 PRESIDENT AND CEO, Director, 10%+ Owner
SPRY ARS Pharmaceuticals, Inc. Apr 19, 2024 4 $200K 4 Apr 22, 2024 PRESIDENT AND CEO, Director, 10%+ Owner
SPRY ARS Pharmaceuticals, Inc. Apr 16, 2024 2 -$928K 4 Apr 17, 2024 PRESIDENT AND CEO, Director, 10%+ Owner
SPRY ARS Pharmaceuticals, Inc. Apr 9, 2024 2 -$928K 4 Apr 10, 2024 PRESIDENT AND CEO, Director, 10%+ Owner
SPRY ARS Pharmaceuticals, Inc. Mar 22, 2024 4 -$890K 4 Mar 26, 2024 PRESIDENT AND CEO, Director, 10%+ Owner
SPRY ARS Pharmaceuticals, Inc. Mar 19, 2024 4 -$21.6K 4 Mar 21, 2024 PRESIDENT AND CEO, Director, 10%+ Owner
SPRY ARS Pharmaceuticals, Inc. Mar 13, 2024 6 -$914K 4 Mar 15, 2024 PRESIDENT AND CEO, Director, 10%+ Owner
SPRY ARS Pharmaceuticals, Inc. Feb 29, 2024 3 -$34.1K 4 Mar 1, 2024 PRESIDENT AND CEO, Director, 10%+ Owner
SPRY ARS Pharmaceuticals, Inc. Feb 26, 2024 6 -$897K 4 Feb 28, 2024 PRESIDENT AND CEO, Director, 10%+ Owner
SPRY ARS Pharmaceuticals, Inc. May 17, 2023 6 $0 4 Jan 4, 2024 President and CEO, Director, 10%+ Owner
SPRY ARS Pharmaceuticals, Inc. Jan 3, 2023 2 $0 4 Jan 5, 2023 President and CEO, Director, 10%+ Owner
SPRY ARS Pharmaceuticals, Inc. Nov 8, 2022 8 $0 4 Nov 10, 2022 President and CEO, Director, 10%+ Owner
SPRY ARS Pharmaceuticals, Inc. Nov 8, 2022 0 $0 3 Nov 10, 2022 President and CEO, Director, 10%+ Owner